GlassScriptPhysician profile
Herman Gist
NPI 1275528234
$2,038.76
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $231 · 2021: $76.88 · 2022: $184 · 2023: $532.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $326.59 | 2019-2023 | |
| Gilead Sciences, INC. | $272.89 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $199.06 | 2019-2023 | Lifevest |
| Pfizer INC. | $167.81 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $138.54 | 2019-2020 | |
| Boston Scientific Corporation | $115.24 | 2019 | |
| Amgen INC. | $105.20 | 2019-2023 | Repatha |
| Astrazeneca Pharmaceuticals LP | $95.72 | 2019-2020 | |
| Abbott Laboratories | $86.18 | 2019-2023 | Aveir, Thoratec Heartmate 3 Lvas Implant Kit |
| Novo Nordisk INC | $77.91 | 2022-2023 | Rybelsus, Ozempic |
| Irhythm Technologies, INC. | $75.47 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.23 | 2023 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $53.54 | 2019 | |
| Medtronic, INC. | $48.52 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $48.26 | 2019-2023 | Camzyos |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $40.22 | 2023 | Opsumit |
| Medtronic Vascular, INC. | $36.66 | 2019 | |
| Atricure, INC. | $26.08 | 2023 | |
| Cardiovascular Systems INC. | $24.04 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $20.18 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $19.42 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Herman Gist listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.